[Featured Stock] Zetema Rises Over 7% on Expectations of Domestic Approval for Toxin

Jitema's stock price is on the rise, with expectations of improved performance through toxin approval within the year. As of 10:05 AM on the 25th, Jitema was trading at 19,370 KRW, up 1,330 KRW (7.37%) from the previous trading day.

On this day, Dalmi Lee, a researcher at BNK Investment & Securities, stated about Jitema, "The biggest investment point is the domestic MFDS approval of the toxin, which is expected to be possible within next month. After approval, full-scale sales will begin from next year," maintaining a buy rating and a target price of 23,000 KRW.

Jitema's standalone performance for the third quarter of this year showed sales of 14 billion KRW and operating profit of 1.6 billion KRW, down 1.2% and 2.1% respectively compared to the same period last year, showing sluggishness. Researcher Lee said, "In the fourth quarter of this year, filler sales that were unrealized in the third quarter are expected to be recognized normally, and due to the peak season effect in the fourth quarter, filler sales are expected to exceed 10 billion KRW," adding, "Toxin sales are expected to be at a similar level to the third quarter."

Performance is expected to improve significantly from next year. Annual sales for next year are projected to increase by 33.8% from this year to 86.8 billion KRW, and operating profit is expected to increase by 64.4% to 16.5 billion KRW due to increased high-margin toxin sales. Researcher Lee forecasted, "First, toxin sales in the domestic market and Turkey are expected to be recognized from the second half of next year, with annual sales projected at 21 billion KRW. Filler is expected to receive Chinese regulatory approval in the first half of next year, and sales are expected to begin in the second half, reaching 55.8 billion KRW annually."